Lantheus price target raised to $115 from $94 at Truist

Truist raised the firm’s price target on Lantheus to $115 from $94 and keeps a Buy rating on the shares. The analyst updates the firm’s model, stating that further diligence and a reimbursement input from key opinion leaders suggest that Truist was "too conservative" on expected Pylarify average selling price decline assumptions starting in 2025. The firm adds that its new model now assumes less Pylarify pricing pressure and more modest share loss into the out-years vs. its prior view.